Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer

Sponsor
Sichuan Cancer Hospital and Research Institute
Study ID
NCT03262545
Phase
PHASE2
Status
Unknown

Conditions

  • Angiogenesis Inhibitors，Ovarian Neoplasms

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • apatinib — DRUG
    Patients in experimental group will take 500mg apatinib daily orally，and patients in control group will take placebo
  • Placebos — DRUG
    Physical properties of placebos are consistent with apatinib

Study Details

The study is to investigate the efficacy and safety of apatinib in patients with advanced ovarian cancer,who has received second-line chemotherapy and failed.

Key Dates

Start date
Aug 27, 2017
Status verified
Aug 2017
Primary completion
Aug 31, 2020
Completion
Feb 28, 2021

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: experimental group
    apatinib 500 mg p.o. once daily
  • Placebo Comparator: control group
    placebo p.o. once daily

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: approximately 2 years ]

Central Contacts